Opko Health, Inc. (OPK)
Nasdaq · Pharmaceutical Preparations · Manufacturing · CIK 944809 · fiscal year ends in Dec
Closing price $1.67 on 29 Oct 2026; 52-week range $1.10 to $1.73.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $587.9M
- Revenue growth
- -11.5%
- Net income, last twelve months
- -$72.9M
- Earnings per share
- -$0.09
- Gross margin
- 40.8%
- Operating margin
- -8.2%
- Net margin
- -12.4%
- Free cash flow
- -$134.0M
- Return on equity
- -6.2%
- Market value
- $1.2B
- Cash
- $300.8M
- Debt
- $349.1M
- Debt to equity
- 0.29
- Shares outstanding
- 746.3M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $606.9M | -$117.4M | -$225.7M | -$0.30 | -$190.8M | 10-K filed 26 Feb 2026 |
| FY2024 | 31 Dec 2024 | $713.1M | -$152.1M | -$53.2M | -$0.08 | -$208.5M | 10-K filed 3 Mar 2025 |
| FY2023 | 31 Dec 2023 | $863.5M | -$157.0M | -$188.9M | -$0.25 | -$44.5M | 10-K filed 1 Mar 2024 |
| FY2022 | 31 Dec 2022 | $1.0B | -$226.3M | -$328.4M | -$0.46 | -$119.8M | 10-K filed 27 Feb 2023 |
| FY2021 | 31 Dec 2021 | $1.8B | $18.8M | -$30.1M | -$0.05 | $6.2M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $163.6M | -$8.4M | -$0.01 |
| Q1 FY2026 | 31 Mar 2026 | $124.2M | -$54.8M | -$0.07 |
| Q4 FY2025 | 31 Dec 2025 | $148.5M | -$31.3M | -$0.04 |
| Q3 FY2025 | 30 Sep 2025 | $151.7M | $21.6M | $0.03 |
| Q2 FY2025 | 30 Jun 2025 | $156.8M | -$148.4M | -$0.19 |
| Q1 FY2025 | 31 Mar 2025 | $150.0M | -$67.6M | -$0.10 |
| Q4 FY2024 | 31 Dec 2024 | $183.6M | $14.0M | $0.01 |
| Q3 FY2024 | 30 Sep 2024 | $173.6M | $24.9M | $0.03 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $436.1M | 71.9% |
| CL | $62.4M | 10.3% |
| Ireland | $51.4M | 8.5% |
| Spain | $26.7M | 4.4% |
| Mexico | $25.5M | 4.2% |
| Other Countries | $4.3M | 0.7% |
| Israel | $522.0K | 0.1% |
Company events
The newest 8-K filings of 260 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 15 Oct 2026 | 8-K | Material agreement | 1.01, 9.01 |
| 2 Oct 2026 | 8-K | Other events | 8.01 |
| 14 Aug 2026 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 27 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 18 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 28 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 19 Mar 2026 | 8-K | Leadership change | 5.02 |
| 26 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 29 Oct 2025 | 8-K | Results | 2.02, 9.01 |
| 15 Sep 2025 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 31 Jul 2025 | 8-K | Results | 2.02, 9.01 |
| 29 May 2025 | 8-K | Leadership change | 5.02 |
Every filing
The newest filings with the SEC of 724 held.
| Filed | Form | Period |
|---|---|---|
| 15 Oct 2026 | 8-K | 14 Oct 2026 |
| 2 Oct 2026 | 8-K | 30 Sep 2026 |
| 28 Aug 2026 | 10-Q/A | 30 Jun 2026 |
| 28 Aug 2026 | 10-Q/A | 31 Mar 2026 |
| 14 Aug 2026 | 8-K | 13 Aug 2026 |
| 27 Jul 2026 | 10-Q | 30 Jun 2026 |
| 27 Jul 2026 | 8-K | 27 Jul 2026 |
| 18 Jun 2026 | 8-K | 18 Jun 2026 |
| 15 May 2026 | DEFA14A | – |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 30 Apr 2026 | DEFA14A | – |
| 30 Apr 2026 | DEF 14A | 30 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 20 Mar 2026 | Paganelli John A, Director | Purchase | 10,000 | $1.14 | $11.3K | 394,340 | 20 Mar 2026 |
| 21 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 102,371 | $1.30 | $133.1K | 216,228,819 | 21 Nov 2025 |
| 21 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 3,894 | $1.32 | $5.1K | 216,232,713 | 21 Nov 2025 |
| 21 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 89,375 | $1.32 | $118.4K | 216,322,088 | 21 Nov 2025 |
| 21 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 191,490 | $1.33 | $254.7K | 216,513,578 | 21 Nov 2025 |
| 21 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 192,870 | $1.33 | $257.5K | 216,706,448 | 21 Nov 2025 |
| 20 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 119,129 | $1.32 | $157.3K | 215,665,577 | 20 Nov 2025 |
| 20 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 47,105 | $1.32 | $62.4K | 215,712,682 | 20 Nov 2025 |
| 20 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 211,948 | $1.33 | $281.9K | 215,924,630 | 20 Nov 2025 |
| 20 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 161,818 | $1.33 | $216.0K | 216,086,448 | 20 Nov 2025 |
| 20 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 24,579 | $1.34 | $32.9K | 216,111,027 | 20 Nov 2025 |
| 20 Nov 2025 | Frost Phillip Md Et Al, CEO & Chairman | Purchase | 1,757 | $1.34 | $2.4K | 216,112,784 | 20 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 1 Jul 2026 | FROST PHILLIP MD ET AL | 13D amended | 34.1% | 255.4M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 34.0M | -4.36% | 5.26 |
| 30 Sep 2026 | 35.6M | -1.19% | 14.94 |
| 15 Sep 2026 | 36.0M | +4.14% | 10.55 |
| 31 Aug 2026 | 34.6M | +2.7% | 13.77 |
| 14 Aug 2026 | 33.6M | +2.33% | 12.37 |
| 31 Jul 2026 | 32.9M | -2.26% | 5.39 |
| 15 Jul 2026 | 33.6M | +3.22% | 12.96 |
| 30 Jun 2026 | 32.6M | -0.59% | 8.93 |
Funds that hold it
From each fund's latest Form 13F.
254 funds held it at 30 Jun 2026: 96 added and 48 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Rubric Capital Management LP | 47,791,243 | $71.7M | 0 |
| BlackRock, Inc. | 36,978,893 | $55.5M | +746,670 |
| Vanguard Capital Management LLC | 14,968,930 | $22.5M | +469,766 |
| Vanguard Portfolio Management LLC | 14,934,924 | $22.4M | +165,205 |
| Geode Capital Management, LLC | 11,581,027 | $17.4M | +279,526 |
| State Street Corp. | 10,309,070 | $15.5M | +807,693 |
| Goldman Sachs Group Inc. | 7,035,492 | $10.6M | -639,534 |
| UBS Group AG | 5,006,284 | $7.5M | -1,065,148 |
| Whitefort Capital Management, LP | 4,511,412 | $6.8M | +258,072 |
| Northern Trust Corp. | 3,756,163 | $5.6M | +136,817 |
Peers
Companies in the same industry.
- Eli Lilly & Co. (LLY): revenue $86.5B, market value $1.29T
- Johnson & Johnson (JNJ): revenue $99.3B, market value $662.4B
- AbbVie Inc. (ABBV): revenue $64.4B, market value $513.9B
- Merck & Co., Inc. (MRK): revenue $66.6B, market value $361.0B
- Novartis AG (NVS): revenue $54.5B, market value $307.3B
- AstraZeneca PLC (AZN): revenue $58.7B, market value $270.6B
- Abbott Laboratories (ABT): revenue $46.6B, market value $180.9B
- Novo Nordisk A/S (NVO): revenue $46.8B, market value $174.8B
- Pfizer Inc. (PFE): revenue $63.7B, market value $170.7B
- Vertex Pharmaceuticals Inc. (VRTX): revenue $12.6B, market value $136.8B